Consumers and payers for health care products and services are increasingly demanding ♦ evidence of treatment benefits and are basing decisions on comparative evidence of effectiveness, as opposed to relying solely on evidence derived from a placebo-based trial or analysis. Payers need to have a means to assess a drug's value in terms of health outcomes ♦ (effectiveness) and expense (costs).
In case of insufficient evidence on relative effectiveness or incremental cost-effectiveness, payers ♦ have turned to novel approaches that base reimbursement on the eventual outcome realized. This literature review provides a summary and analysis of the current literature on these ♦ relatively new, novel, and outcomes-based reimbursement agreements.
The literature review suggests that many risk-sharing agreements are not published and ♦ those that are vary widely in design, scope, and intent. The search resulted in 61 abstracts which identified 8 risk-sharing schemes; 1 additional ♦ more recent study was identified from Grey Literature to yield 9 schemes. The published risk-sharing schemes were from the United Kingdom (n=3), United States ♦ (n=3), France (n=1), Italy (n=1), and Sweden (n=1). Figure 1 depicts a taxonomy based upon individual patient and patient populations. The ♦ terms of settlement link reimbursement and outcome as measured by response or cost effectiveness.
These agreements manifest themselves in different ways and under different names based on the country in which they are negotiated and/or the companies that undertake them. The commonality of tying pharmaceutical reimbursement or recommendation for adoption to health outcomes makes them globally identifiable. For this study:
Any reimbursement or adoption scheme in which health outcomes resulting from the use of ♦ technology are used as the basis to make funding decisions are considered relevant. These agreements go by various names throughout the literature which include: value-based pricing, risk-sharing agreements, pay-for-outcomes, access schemes, conditional coverage, coverage with evidence development, and performance-based pricing. Related concepts like Value-based Benefit Design (VBBD) and Pay-for-performance or ♦ incentives for healthcare providers are not included within the scope of this review.
The term "outcomes-based" will be utilized as the common, all-inclusive term when not ♦ referring to a specific prior source. Otherwise, specific terminology will be applied as it is stated within each source document.
Risk-sharing agreements offer the opportunity for payers and manufacturers to share ♦ the risk of developing and paying for a new technology, ultimately to the benefit of the patients. Linking health outcomes to payments ensures that patients and payers are getting the ♦ most value possible for their money by only paying for what works; pharmaceutical manufacturers are able to enter a marketplace while proving their drug's value in real world settings. In the absence of long term data, payment and reimbursement schemes will continue to ♦ become more popular among those paying for new technologies. The literature has demonstrated that this trend is already growing in Europe and North ♦ America. With a better understanding of the advantages of the schemes, they may also be adopted in other regions. 
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Sitagliptin and Sitaglyptin+Metformin (Januvia and Janumet) Merck entered into a more unusual arrangement with CIGNA for the diabetes drugs ♦ Janumet and Januvia. Merck agreed to give bigger discounts if:
Patients were adherent and persistent with Januvia and/or Janumet. ♦ Patients' blood sugar is better controlled regardless of the source of improvement ♦ (Januvia/Janumet or other medications).
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From the manufacturer's perspective, lower prices are expected to be offset by an increase ♦ in sales volume, thereby making the agreement economically advantageous. The manufacturers proposed taking on payment for bone fractures occurring while the ♦ patient is taking Actonel. Qualifying patients (non-comorbid, no prior fractures, etc.) that have taken Actonel for six ♦ out of the nine most recent months will have any health costs associated with a non-spinal fracture covered by the manufacturing companies 3 (estimated to cost between $6,000 and $30,000 per fracture, depending on the fracture location 4 ). Health Alliance has an incentive to keep qualified patients on Actonel instead of switching ♦ to a less-expensive generic alternative because this agreement reduced their potential treatment costs for fracture treatment for patients on Actonel. Health Alliance also encourages more to consider Actonel's use by keeping it on a lower ♦ formulary tier than competing brand-name drug, Boniva (ibandronate).

Ranibizumab (Lucentis)
Novartis entered into an agreement with the UK-NHS for Lucentis used for wet Age-♦ Related Macular Degeneration (AMD). This followed a favorable recommendation from NICE (that is, NICE recommended it for ♦ funding on the basis that it was cost-effective)
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, but was limited to a course of treatment not to exceed 14 injections of Lucentis.
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To avoid this limitation, Novartis agreed to pay for any injections of Lucentis that exceeded ♦ the 14 recommended by NICE, thereby making the additional injections free to both the patient and health care system within the timelines defined in the scheme.
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The approach helped to protect Lucentis' place in the market and ensure that patients ♦ could continue their treatment.
It also had the advantage of a lower overall cost to the NHS for the improved outcome, thus ♦ lowering its cost-effectiveness ratio and making it more attractive for adoption.
Objectives:
To assess and analyze the number, type, and extent of risk-sharing agreements worldwide based on published literature.
Methods:
A structured literature review using predefined search criteria was conducted to identify references to, or descriptions of, health outcome-based risk-sharing agreements within peer-reviewed and trade publications between the years of 2000-2009. The identified publications were categorized by strength of evidence (i.e., systematic or nonsystematic), and then aggregated by type of agreement, technology, and companies involved within the agreement. Analysis was completed to demonstrate commonalities among identified agreements as well as their unique aspects.
Results: Five database and publication sources were reviewed using 17 predefined search terms. The literature review suggests that many risk-sharing agreements are not published and those that are vary widely in design, scope, and intent. The search resulted in 61 abstracts which identified 8 individual published risk-sharing schemes. While all identified agreements link improvements in health outcomes with reimbursement, definitions of what constitutes improved health outcomes, as well as the type of evidence required to prove that improvement, varied dramatically. The published risk-sharing schemes were from the United Kingdom (n=3), United States (n=3), France (n=1), and Sweden (n=1). There is more publically available information on agreements outside of the US, but it is unclear the extent to which this is due to greater transparency in reimbursement versus a reflection of more risk-sharing agreements.
Conclusions: Health outcomes-based risk-sharing agreements offer the potential for both benefit and frustration to manufacturers and payers alike. The ability to review progress within this field to-date and attempt to offer trends towards best practices will be key to the long-term viability of these novel reimbursement efforts. Despite the heterogeneity of agreement types, methods, and foci, successful utilization of these agreements has been achieved and could potentially offer a guide for replication in future use.
The objectives of this study were to assess and analyze the number, type, and extent of risksharing agreements worldwide based on published literature.
OBJeCTiVeS
A structured literature review using predefined search criteria was conducted to identify ♦ references to, or descriptions of, health outcome-based risk-sharing agreements within peer-reviewed and trade publications between the years of 2000-2009. Five database and publication sources were reviewed including:
The Pink Sheet ♦ The New York Times ♦ Pharmaceutical Executive ♦ Scrip World Pharmaceutical News ♦ The identified publications were categorized by strength of evidence assessed by ♦ the quality of reviews and then aggregated by type of agreement, technology, and companies involved within the agreement.
Analysis was completed to demonstrate commonalities and unique aspects of agreements, ♦ and a taxonomy designed.
MeTHODS Figure 1. Detailed Taxonomy of Outcomes Based (Outcomes Guarantee) Reimbursement Schemes
All identified agreements showed a link between improvements in health outcomes with ♦ reimbursement. Definitions of what was considered an improved health outcome, as well as the type of ♦ evidence required to prove the improvement varied dramatically for the agreements.
